NEW YORK ( TheStreet) -- CHANGE IN RATINGS Apple ( AAPL) rated new Neutral at Nomura. $710 price target. Growth could decelerate by 2014. Allot Communications ( ALLT) upgraded at Jefferies to Buy from Hold, Jefferies said. $30 price target. Verizon will soon begin ramping. Aruba Networks ( ARUN) upgraded to hold at TheStreet Ratings. HomeAway ( AWAY) upgraded to hold at TheStreet Ratings. Cardinal Health ( CAH) upgraded at ISI from Market Weight to Overweight, ISI Group said. $46 price target. Stock is already factoring in pricing fears with WAG and CVS. Caterpillar ( CAT) rated new Neutral at Piper. $90 price target. Mining segment is a long term strength, but an overhang in 2013. Cymer ( CYMI) rated new Outperform at CLSA. $60 price target. Leading stepper light source supplier. Dell ( DELL) rated new Sell at Citigroup. $8.50 price target. BYOD trends should pressure shares. DirecTV ( DTV) downgraded at JP Morgan from Overweight to Neutral, JP Morgan said. $58 price target. Company will likely buy back fewer shares in the coming quarters. Edison International ( EIX) downgraded at Jefferies to Hold from Buy, Jefferies said. $51 price target. Valuation call. Evercore Partners ( EVR) rated new Neutral at UBS. $28 price target. Dilution risk could limit support the yield provides to the stock. Greenhill ( GHL) rated new Neutral at UBS. $52 price target. Premium valuations restored, further upside seems limited. Hewlett-Packard ( HPQ) rated new Sell at Citigroup. $13.50 price target. Needs clear strategic direction and leadership. IBM ( IBM) rated new Buy at Citigroup. $250 price target. One of the most compelling long term investments in tech. Johnson & Johnson ( JNJ) downgraded at Goldman from Neutral to Sell, Goldman Sachs said. Valuation call, based on a $72 price target. Lazard ( LAZ) rated new Sell at UBS. $25 price target. Solid mature business, but valuation and expectations stretched. Eli Lilly ( LLY) upgraded at Goldman from Sell to Neutral, Goldman Sachs said. $54 price target. Sola could reach the market in 3 to 4 years. Netflix ( NFLX) downgraded at BofA/Merrill from Buy to Underperform, Bank of America/Merrill Lynch said. $72 price target. Valuation call, as the stock is up 31% over the past two weeks.
PACCAR ( PCAR) rated new Overweight at Piper. $48.50 price target. Best positioned to benefit from a return to growth in the North American truck market. Pier 1 Imports ( PIR) rated new Buy at Deutsche. $25 price target. Company is leveraged to positive industry trends. Progressive ( PRGS) downgraded at Mizuho from Buy to Neutral, Mizuho said. $14.50 price target. Company is losing a key leader, which it will struggle to replace. Pioneer Natural ( PXD) rated new Outperform at Wells. Wolfcamp play should drive near-term growth. Questcor Pharmaceuticals ( QCOR) upgraded at Jefferies to Buy from Hold, Jefferies said. $28 price target. Limited downside with improved visibility. Vertex Pharmaceuticals ( VRTX) rated new Buy at Deutsche. $77 price target. New cystic fibrosis drug should be the next main driver.
Twitter and become a fan on Facebook.
STOCK COMMENTS / EPS CHANGESMoody's ( MCO) estimates, target increased at Piper. MCO estimates were raised through 2013, Piper Jaffray said. Company is leveraged to higher debt issuance rates. Overweight rating and new $55 price target. Pentair ( PNR) estimates, target raised at Credit Suisse. Shares of PNR now seen reaching $54, according to Credit Suisse. Estimates also increased, as the Tyco deal should add to earnings. Neutral rating. Riverbed ( RVBD) estimates, target boosted at ThinkEquity. Shares of RVBD now seen reaching $26, according to ThinkEquity. Estimates also upped, given higher expected demand and pricing. Buy rating. >To submit a news tip, email: email@example.com.
READERS ALSO LIKE:
Twitter and become a fan on Facebook.